Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review
- PMID: 30806700
- DOI: 10.1001/jama.2019.0131
Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review
Abstract
Importance: There are 30 million adults (12%) in the United States who have chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for 3.2% of all physician office visits annually and is the fourth leading cause of death (126 000 deaths per year). Most patients are diagnosed by their primary care clinicians who must address the highly variable clinical features and responses to therapy. The diagnosis and treatment of COPD is rapidly changing, so understanding recent advances is important for the delivery of optimal patient care.
Observations: Chronic obstructive pulmonary disease is characterized by incompletely reversible expiratory airflow limitation. Spirometry is the reference standard for diagnosing and assessing the severity of COPD. All patients should be counseled about and receive preventive measures such as smoking cessation and vaccination. Treatment should be guided by the severity of lung impairment, symptoms such as dyspnea, the amount of cough and sputum production, and how often a patient experiences an exacerbation. When dyspnea limits activity or quality of life, COPD should be treated with once- or twice-daily maintenance long-acting anticholinergic and β-agonist bronchodilators. Patients with acute exacerbations may benefit from the addition of inhaled corticosteroids, particularly those with elevated peripheral eosinophil levels. Pulmonary rehabilitation, which includes strength and endurance training and educational, nutritional, and psychosocial support, improves symptoms and exercise tolerance but is underutilized. Supplemental oxygen for patients with resting hypoxemia (defined as Spo2 <89%) improves survival.
Conclusions and relevance: Chronic obstructive pulmonary disease is a complicated disease requiring intensive treatment. Appropriate use of long-acting maintenance bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation decreases symptoms, optimizes functional performance, and reduces exacerbation frequency. Supplemental oxygen in patients with resting hypoxemia prolongs life, and other advanced treatments are available based on specific patient characteristics.
Similar articles
-
Common lung conditions: chronic obstructive pulmonary disease.FP Essent. 2013 Jun;409:23-31. FP Essent. 2013. PMID: 23767419
-
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.Ann Intern Med. 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008. Ann Intern Med. 2011. PMID: 21810710
-
[Long-term treatment strategy in chronic obstructive pulmonary disease: how to change the course of the disease].Presse Med. 2014 Dec;43(12 Pt 1):1368-80. doi: 10.1016/j.lpm.2014.09.009. Epub 2014 Nov 1. Presse Med. 2014. PMID: 25455634 Review. French.
-
Contemporary issues in the care of patients with chronic obstructive pulmonary disease.J Manag Care Pharm. 2005 Jun;11(5 Suppl A):S2-13; quiz S14-6. doi: 10.18553/jmcp.2005.11.s5-a.1. J Manag Care Pharm. 2005. PMID: 15934804 Free PMC article. Review.
-
Contemporary management of chronic obstructive pulmonary disease: scientific review.JAMA. 2003 Nov 5;290(17):2301-12. doi: 10.1001/jama.290.17.2301. JAMA. 2003. PMID: 14600189 Review.
Cited by
-
Prognostic Value of Leukocyte-Based Risk Model for Acute Kidney Injury Prediction in Critically Ill Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients.Int J Chron Obstruct Pulmon Dis. 2024 Mar 4;19:619-632. doi: 10.2147/COPD.S444888. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 38464562 Free PMC article.
-
Time trends in limited lung function among German middle-aged and older adults.Sci Rep. 2024 Feb 29;14(1):5036. doi: 10.1038/s41598-024-55624-2. Sci Rep. 2024. PMID: 38424128 Free PMC article.
-
Bufei Yishen formula protects the airway epithelial barrier and ameliorates COPD by enhancing autophagy through the Sirt1/AMPK/Foxo3 signaling pathway.Chin Med. 2024 Feb 28;19(1):32. doi: 10.1186/s13020-024-00905-1. Chin Med. 2024. PMID: 38413976 Free PMC article.
-
Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOx.BMJ Open Respir Res. 2023 Dec 26;10(1):e001710. doi: 10.1136/bmjresp-2023-001710. BMJ Open Respir Res. 2023. PMID: 38151258 Free PMC article.
-
Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov 22. doi: 10.1007/s00210-023-02830-w. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 37991539 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
